Ali Hashim, Naseem Asma, Siddiqui Zaheenul Islam
Department of Pathology, University of Cambridge, Addenbrookes Hospital, Cambridge CB2 0QQ, UK.
Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1DZ, UK.
J Clin Med. 2023 Sep 20;12(18):6079. doi: 10.3390/jcm12186079.
SARS-CoV-2 infection induces non-physiological syncytia when its spike fusogenic protein on the surface of the host cells interacts with the ACE2 receptor on adjacent cells. Spike-induced syncytia are beneficial for virus replication, transmission, and immune evasion, and contribute to the progression of COVID-19. In this review, we highlight the properties of viral fusion proteins, mainly the SARS-CoV-2 spike, and the involvement of the host factors in the fusion process. We also highlight the possible use of anti-fusogenic factors as an antiviral for the development of therapeutics against newly emerging SARS-CoV-2 variants and how the fusogenic property of the spike could be exploited for biomedical applications.
当严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染时，其在宿主细胞表面的刺突融合蛋白与相邻细胞上的血管紧张素转换酶2（ACE2）受体相互作用，会诱导形成非生理性合胞体。刺突诱导的合胞体有利于病毒复制、传播和免疫逃逸，并促进冠状病毒病2019（COVID-19）的进展。在这篇综述中，我们重点介绍了病毒融合蛋白的特性，主要是SARS-CoV-2刺突蛋白，以及宿主因子在融合过程中的作用。我们还重点介绍了抗融合因子作为抗病毒药物在开发针对新出现的SARS-CoV-2变体的治疗方法中的可能用途，以及如何利用刺突蛋白的融合特性进行生物医学应用。
Zotero 插件
